Drug intelligence / Profile preview

Neu-14E

Development stage: Preclinical
Lead developer: Neurim Pharmaceuticals
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

Neu-14E is a preclinical-stage small molecule drug candidate being developed by Neurim Pharmaceuticals for the treatment of fibrosis. While specific details regarding its molecular target and mechanism of action are not publicly disclosed, the compound is part of Neurim's pipeline of novel chemical entities. Neurim Pharmaceuticals generally focuses on the discovery and development of drugs that modulate neuroendocrine and circadian pathways, often leveraging expertise in melatonin receptor signaling, though Neu-14E represents an expansion of their portfolio into fibrotic indications.

Beyond the preview

Go deeper on Neu-14E.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neu-14E.

Explore the full profile